• Je něco špatně v tomto záznamu ?

Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements

F. Zitricky, A. Försti, A. Hemminki, O. Hemminki, K. Hemminki

. 2023 ; 15 (16) : . [pub] 20230816

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23015446

Grantová podpora
856620 European Commission

BACKGROUND: The incidence of prostate cancer (PC) increased vastly as a result of prostate-specific antigen (PSA) testing. Survival in PC improved in the PSA-testing era, but changes in clinical presentation have hampered the interpretation of the underlying causes. DESIGN: We analyzed survival trends in PC using data from the NORDCAN database for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) by analyzing 1-, 5- and 10-year relative survival and conditional relative survival over the course of 50 years (1971-2020). RESULTS: In the pre-PSA era, survival improved in FI and SE and improved marginally in NO but not in DK. PSA testing began toward the end of the 1980s; 5-year survival increased by approximately 30%, and 10-year survival improved even more. Conditional survival from years 6 to 10 (5 years) was better than conditional survival from years 2 to 5 (4 years), but by 2010, this difference disappeared in countries other than DK. Survival in the first year after diagnosis approached 100%; by year 5, it was 95%; and by year 10, it was 90% in the best countries, NO and SE. CONCLUSIONS: In spite of advances in diagnostics and treatment, further attention is required to improve PC survival.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23015446
003      
CZ-PrNML
005      
20231020093447.0
007      
ta
008      
231010s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/cancers15164132 $2 doi
035    __
$a (PubMed)37627160
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Zitricky, Frantisek $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, 30605 Pilsen, Czech Republic
245    10
$a Conditional Survival in Prostate Cancer in the Nordic Countries Elucidates the Timing of Improvements / $c F. Zitricky, A. Försti, A. Hemminki, O. Hemminki, K. Hemminki
520    9_
$a BACKGROUND: The incidence of prostate cancer (PC) increased vastly as a result of prostate-specific antigen (PSA) testing. Survival in PC improved in the PSA-testing era, but changes in clinical presentation have hampered the interpretation of the underlying causes. DESIGN: We analyzed survival trends in PC using data from the NORDCAN database for Denmark (DK), Finland (FI), Norway (NO) and Sweden (SE) by analyzing 1-, 5- and 10-year relative survival and conditional relative survival over the course of 50 years (1971-2020). RESULTS: In the pre-PSA era, survival improved in FI and SE and improved marginally in NO but not in DK. PSA testing began toward the end of the 1980s; 5-year survival increased by approximately 30%, and 10-year survival improved even more. Conditional survival from years 6 to 10 (5 years) was better than conditional survival from years 2 to 5 (4 years), but by 2010, this difference disappeared in countries other than DK. Survival in the first year after diagnosis approached 100%; by year 5, it was 95%; and by year 10, it was 90% in the best countries, NO and SE. CONCLUSIONS: In spite of advances in diagnostics and treatment, further attention is required to improve PC survival.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Försti, Asta $u Hopp Children's Cancer Center (KiTZ), 69120 Heidelberg, Germany $u Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), 69120 Heidelberg, Germany $1 https://orcid.org/0000000298574728
700    1_
$a Hemminki, Akseli $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland $u Comprehensive Cancer Center, Helsinki University Hospital, 00029 Helsinki, Finland $1 https://orcid.org/0000000171038530
700    1_
$a Hemminki, Otto $u Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, 00290 Helsinki, Finland $u Department of Urology, Helsinki University Hospital, 00029 Helsinki, Finland
700    1_
$a Hemminki, Kari $u Biomedical Center, Faculty of Medicine, Charles University Pilsen, 30605 Pilsen, Czech Republic $u Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, 69120 Heidelberg, Germany $1 https://orcid.org/0000000227693316 $7 mzk20201092711
773    0_
$w MED00173178 $t Cancers $x 2072-6694 $g Roč. 15, č. 16 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37627160 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20231010 $b ABA008
991    __
$a 20231020093441 $b ABA008
999    __
$a ok $b bmc $g 1997141 $s 1201808
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 15 $c 16 $e 20230816 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
GRA    __
$a 856620 $p European Commission
LZP    __
$a Pubmed-20231010

Najít záznam

Citační ukazatele

Možnosti archivace